BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36

Benzinga Newsdesk www.benzinga.com Positive 57.3%

Neg 0% Neu 0% Pos 57.3%

BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Outperform rating and announces Price Target of $36.